Brofaromine versus lithium addition to maprotiline. A double-blind study in maprotiline refractory depressed outpatients.

Abstract

Depressed outpatients (n = 51) resistant to treatment with maprotiline were treated in a blind, randomized, single-centre study, for 6 weeks with either the reversible and selective monoamine oxidase A-inhibitor (MAO-A-I), brofaromine or lithium addition to maprotiline. The Hamilton Rating Scale for Depression was scored by an independent rater before and after the 6 week treatment period. No significant differences in efficacy were found between the two treatment regimes. In the patients who completed the trial, brofaromine was well tolerated with the exception of insomnia. Anticholinergic effects as well as thyroid dysfunctions (17 out of 20) were more frequent in the maprotiline/lithium group.

• Authors: E Hoencamp, P M Haffmans, W A Dijken, C A Hoogduin, W A Nolen, R van Dyck
• Journal: Journal of affective disorders (J Affect Disord) Vol. 30 Issue 3 Pg. 219-27 (Mar 1994) ISSN: 0165-0327 [Print] Netherlands
• PMID: 8006248 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Monoamine Oxidase Inhibitors
• Piperidines
• Maprotiline
• brofaromine
• Lithium

Topics

• Adolescent
• Adult
• Aged
• Depressive Disorder (drug therapy, psychology)
• Double-Blind Method
• Drug Therapy, Combination
• Female
• Humans
• Lithium (administration & dosage, adverse effects)
• Male
• Maprotiline (administration & dosage, adverse effects)
• Middle Aged
• Monoamine Oxidase Inhibitors (administration & dosage, adverse effects)
• Personality Inventory
• Piperidines (administration & dosage, adverse effects)
• Prospective Studies
• Recurrence